In response to COVID-19, GHX is committed to helping ensure that our customers receive access to the data and information needed to help maintain critical supplies to serve patients and protect staff. Click to learn more
Log In

Does the evidence support Exparel’s high price tag?

Approved for use in 2011, Exparel is a local anesthetic used to treat postoperative pain, for example in hip and knee surgery. US health systems spend upwards of $300M annually on Exparel. Despite limited evidence of superiority over older anesthetics, Exparel is priced 10x higher than comparators.

View this on-demand presentation featuring Lumere experts Samantha Bastow, PharmD, and Grace Fox, PhD, to explore takeaways from the most recently published studies related to Exparel and learn more about if and when to integrate it into your formulary to drive value-based care.